Browse the corpus

Walk the evidence base by book and chapter — the raw source passages that ground Ask, Differential, and the rest.

• A clinician's guide to microbiome analysis.1 passage
• A global view of hepatocellular carcinoma: trends, risk, prevention and management.1 passage
• A guide to multimodal endoscopy imaging for gastrointestinal malignancy - an early indicator.1 passage
• A risk-stratified approach to colorectal cancer prevention and diagnosis.1 passage
• AHR in the intestinal microenvironment: safeguarding barrier function.1 passage
• Acid and the basis for cellular plasticity and reprogramming in gastric repair and cancer.1 passage
• Acinar cell plasticity and development of pancreatic ductal adenocarcinoma.1 passage
• Acute graft-versus-host disease of the gut: considerations for the gastroenterologist.1 passage
• Acute severe ulcerative colitis: from pathophysiology to clinical management.1 passage
• Acute-on-chronic liver failure: terminology, mechanisms and management.1 passage
• Adaptive immunity: an emerging player in the progression of NAFLD.1 passage
• Adiposity and gastrointestinal cancers: epidemiology, mechanisms and future directions.1 passage
• Adult and paediatric GERD: diagnosis, phenotypes and avoidance of excess treatments.1 passage
• Advances in image enhancement in colonoscopy for detection of adenomas.1 passage
• Advances in immunotherapy for hepatocellular carcinoma.1 passage
• Advances in use of immunomodulatory agents--a rheumatology perspective.1 passage
• Advancing the global public health agenda for NAFLD: a consensus statement.1 passage
• Alcohol, adipose tissue and liver disease: mechanistic links and clinical considerations.1 passage
• Alcohol, liver disease and the gut microbiota.1 passage
• Alcohol: taking a population perspective.1 passage
• Alcoholic liver disease: mechanisms of injury and targeted treatment.1 passage
• Antidepressants in inflammatory bowel disease.1 passage
• Apoptosis and necroptosis in the liver: a matter of life and death.1 passage
• Autophagy in the liver: functions in health and disease.1 passage
• Bacteriophages and their potential for treatment of gastrointestinal diseases.1 passage
• Bariatric surgery for obesity and metabolic disorders: state of the art.1 passage
• Barrett oesophagus: lessons on its origins from the lesion itself.1 passage
• Behavioural medicine and gastrointestinal disorders: the promise of positive psychology.1 passage
• Big data in IBD: a look into the future.1 passage
• Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis.1 passage
• Bioelectric neuromodulation for gastrointestinal disorders: effectiveness and mechanisms.1 passage
• Bioengineering the gut: future prospects of regenerative medicine.1 passage
• Biologic agents for IBD: practical insights.1 passage
• Biosimilars in IBD: from theory to practice.1 passage
• Brain-gut-microbiome interactions in obesity and food addiction.1 passage
• Breakthroughs in the treatment and prevention of Clostridium difficile infection.1 passage
• COVID-19 and liver disease: mechanistic and clinical perspectives.1 passage
• COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology.1 passage
• Cancer stem cells in hepatocellular carcinoma - from origin to clinical implications.1 passage
• Cancer-associated fibroblasts in gastrointestinal cancer.1 passage
• Caring for children with NAFLD and navigating their care into adulthood.1 passage
• Cell death in pancreatic cancer: from pathogenesis to therapy.1 passage
• Cell death in the gut epithelium and implications for chronic inflammation.1 passage
• Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics.1 passage
• Chemoprevention of hereditary colon cancers: time for new strategies.1 passage
• Childhood functional abdominal pain: mechanisms and management.1 passage
• Cholangiocarcinoma 2020: the next horizon in mechanisms and management.1 passage
• Cholangiocyte pathobiology.1 passage
• Circadian clocks in the digestive system.1 passage
• Circadian rhythms of liver physiology and disease: experimental and clinical evidence.1 passage
• Cirrhosis-associated immune dysfunction.1 passage
• Clinical management of hereditary colorectal cancer syndromes.1 passage
• Clinical measurement of gastrointestinal motility and function: who, when and which test?1 passage
• Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection.1 passage
• Clonal evolution of colorectal cancer in IBD.1 passage
• Clostridium difficile infection: epidemiology, diagnosis and understanding transmission.1 passage
• Coeliac disease and autoimmune disease-genetic overlap and screening.1 passage
• Coeliac disease and gluten-related disorders in childhood.1 passage
• Coeliac disease: to biopsy or not?1 passage
• Colorectal cancer: An intravenous probe for colorectal cancer screening.1 passage
• Congenital diarrhoeal disorders: advances in this evolving web of inherited enteropathies.1 passage
• Consequences of bariatric surgery on oesophageal function in health and disease.1 passage
• Control and dysregulation of redox signalling in the gastrointestinal tract.1 passage
• Critical comparison of elastography methods to assess chronic liver disease.1 passage
• Crosstalk at the mucosal border: importance of the gut microenvironment in IBS.1 passage
• Current and emerging therapeutic targets for IBD.1 passage
• Current and emerging therapies for coeliac disease.1 passage
• Current best practice for disease activity assessment in IBD.1 passage
• Current management of the gastrointestinal complications of systemic sclerosis.1 passage
• Cystic fibrosis from the gastroenterologist's perspective.1 passage
• Defining comprehensive models of care for NAFLD.1 passage
• Developmental origins of NAFLD: a womb with a clue.1 passage
• Diagnosis and management of chronic constipation in adults.1 passage
• Diagnosis and management of pancreatic cystic neoplasms: current evidence and guidelines.1 passage
• Diet and host-microbial crosstalk in postnatal intestinal immune homeostasis.1 passage
• Diet, microorganisms and their metabolites, and colon cancer.1 passage
• Dietary carbohydrates and fats in nonalcoholic fatty liver disease.1 passage
• Dietary fibre in gastrointestinal health and disease.1 passage
• Dietary management of IBD--insights and advice.1 passage
• Direct-acting antiviral agents for HCV infection affecting people who inject drugs.1 passage
• Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights.1 passage
• Disorders of the enteric nervous system - a holistic view.1 passage
• Distinguishing GERD from eosinophilic oesophagitis: concepts and controversies.1 passage
• Dysphagia: current reality and scope of the problem.1 passage
• Early detection of pancreatic cancer using DNA-based molecular approaches.1 passage
• Early-onset colorectal cancer: initial clues and current views.1 passage
• Endoscopic mucosal resection and endoscopic submucosal dissection of large colonic polyps.1 passage
• Energy balance and gastrointestinal cancer: risk, interventions, outcomes and mechanisms.1 passage
• Enteric glial biology, intercellular signalling and roles in gastrointestinal disease.1 passage
• Enteric nervous system: sensory transduction, neural circuits and gastrointestinal motility.1 passage
• Environmental triggers in IBD: a review of progress and evidence.1 passage
• Epidemiology and risk factors for IBD.1 passage
• Epidemiology, risk factors and management of cardiovascular diseases in IBD.1 passage
• Epigenetics of colorectal cancer: biomarker and therapeutic potential.1 passage
• Epithelial Toll-like receptors and their role in gut homeostasis and disease.1 passage
• Evaluation of indeterminate biliary strictures.1 passage
• Evidence-based and mechanistic insights into exclusion diets for IBS.1 passage
• Evolutionary dynamics in Barrett oesophagus: implications for surveillance, risk stratification and therapy.1 passage
• Experimental models of hepatitis B and C - new insights and progress.1 passage
• Expert consensus document: Advances in the diagnosis and classification of gastric and intestinal motility disorders.1 passage
• Expert consensus document: Advances in the evaluation of anorectal function.1 passage
• Expert consensus document: Advances in the management of oesophageal motility disorders in the era of high-resolution manometry: a focus on achalasia syndromes.1 passage
• Expert consensus document: Advances in the physiological assessment and diagnosis of GERD.1 passage
• Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).1 passage
• Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics.1 passage
• Exploring liver cancer biology through functional genetic screens.1 passage
• Extracellular vesicles in liver disease and potential as biomarkers and therapeutic targets.1 passage
• Extrahepatic cancers and chronic HCV infection.1 passage
• Extraintestinal manifestations of coeliac disease.1 passage
• Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology.1 passage
• Fatigue in IBD: epidemiology, pathophysiology and management.1 passage
• First translational consensus on terminology and definitions of colonic motility in animals and humans studied by manometric and other techniques.1 passage
• Food allergy and the gut.1 passage
• From NASH to HCC: current concepts and future challenges.1 passage
• Gastrointestinal aspects of vasculitides.1 passage
• Gastrointestinal bleeding. Gastrointestinal bleeding risk is increased by novel anticoagulants.1 passage
• Gastrointestinal diagnosis using non-white light imaging capsule endoscopy.1 passage
• Gastrointestinal imaging in 2015: Emerging trends in endoscopic imaging.1 passage
• Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management.1 passage
• Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology.1 passage
• Genetics of primary sclerosing cholangitis and pathophysiological implications.1 passage
• Ghrelin and motilin receptors as drug targets for gastrointestinal disorders.1 passage
• Global burden and epidemiology of Barrett oesophagus and oesophageal cancer.1 passage
• Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.1 passage
• Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies.1 passage
• Global burden of irritable bowel syndrome: trends, predictions and risk factors.1 passage
• Global epidemiology and burden of HCV infection and HCV-related disease.1 passage
• Global epidemiology and holistic prevention of pancreatitis.1 passage
• Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.1 passage
• Global strategies are required to cure and eliminate HBV infection.1 passage
• Gut adaptation after metabolic surgery and its influences on the brain, liver and cancer.1 passage
• Gut microbiome as a clinical tool in gastrointestinal disease management: are we there yet?1 passage
• Gut microbiome, big data and machine learning to promote precision medicine for cancer.1 passage
• Gut microbiota - at the intersection of everything?1 passage
• Gut microbiota and IBD: causation or correlation?1 passage
• Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.1 passage
• Gut microbiota as a transducer of dietary cues to regulate host circadian rhythms and metabolism.1 passage
• Gut microbiota in 2015: Prevotella in the gut: choose carefully.1 passage
• Gut microbiota in colorectal cancer: mechanisms of action and clinical applications.1 passage
• Gut microbiota modulation of chemotherapy efficacy and toxicity.1 passage
• Gut microbiota-derived metabolites as key actors in inflammatory bowel disease.1 passage
• Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer.1 passage
• Gut microbiota. Microbiota organization--a key to understanding CRC development.1 passage
• HCV in 2015: Advances in hepatitis C research and treatment.1 passage
• Harnessing big 'omics' data and AI for drug discovery in hepatocellular carcinoma.1 passage
• Harnessing metabolic dependencies in pancreatic cancers.1 passage
• Head-to-head trials in inflammatory bowel disease: past, present and future.1 passage
• Helicobacter pylori infection and antibiotic resistance - from biology to clinical implications.1 passage
• Helicobacter pylori: Helicobacter pylori gastritis--a novel distinct disease entity.1 passage
• Hepatic microcirculation and mechanisms of portal hypertension.1 passage
• Hepatitis delta virus: insights into a peculiar pathogen and novel treatment options.1 passage
• Hepatitis: After HCV cure, HBV cure?1 passage
• Hepatitis: Epigenetic control of HBV by HBx protein--releasing the break?1 passage
• Hirschsprung disease - integrating basic science and clinical medicine to improve outcomes.1 passage
• How to stomach an epigenetic insult: the gastric cancer epigenome.1 passage
• Human biomimetic liver microphysiology systems in drug development and precision medicine.1 passage
• Human mini-guts: new insights into intestinal physiology and host-pathogen interactions.1 passage
• IBD. Regulatory T cells for treatment of Crohn's disease.1 passage
• IBD: Indication extrapolation for anti-TNF biosimilars.1 passage
• IBS and IBD - separate entities or on a spectrum?1 passage
• IBS: biomarkers for IBS: ready for prime time?1 passage
• IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting.1 passage
• IgG4-related diseases of the digestive tract.1 passage
• IgG4-related hepatobiliary disease: an overview.1 passage
• Imaging in pancreatic disease.1 passage
• Immunological landscape and immunotherapy of hepatocellular carcinoma.1 passage
• Immunology in the liver--from homeostasis to disease.1 passage
• Immunopathogenesis of IBD: current state of the art.1 passage
• Immunotherapy in colorectal cancer: rationale, challenges and potential.1 passage
• Infant colic: mechanisms and management.1 passage
• Inflammasome activation and function in liver disease.1 passage
• Inflammasomes in the gastrointestinal tract: infection, cancer and gut microbiota homeostasis.1 passage
• Insights into the success and failure of systemic therapy for hepatocellular carcinoma.1 passage
• International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease.1 passage
• Interrogating host immunity to predict treatment response in inflammatory bowel disease.1 passage
• Intestinal epithelial glycosylation in homeostasis and gut microbiota interactions in IBD.1 passage
• Intestinal gases: influence on gut disorders and the role of dietary manipulations.1 passage
• Intestinal hypoxia and hypoxia-induced signalling as therapeutic targets for IBD.1 passage
• Intestinal lymphatic vasculature: structure, mechanisms and functions.1 passage
• Intra-pancreatic fat deposition: bringing hidden fat to the fore.1 passage
• JAK-STAT pathway targeting for the treatment of inflammatory bowel disease.1 passage
• Keys to long-term care of the liver transplant recipient.1 passage
• Laparoscopic pancreatic surgery for benign and malignant disease.1 passage
• Lessons learned--resolving the enigma of genetic factors in IBS.1 passage
• Leveraging diet to engineer the gut microbiome.1 passage
• Lipid droplets and liver disease: from basic biology to clinical implications.1 passage
• Liver - guardian, modifier and target of sepsis.1 passage
• Liver regeneration - mechanisms and models to clinical application.1 passage
• Liver regeneration: biological and pathological mechanisms and implications.1 passage
• Liver sinusoidal endothelial cells - gatekeepers of hepatic immunity.1 passage
• Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches.1 passage
• Liver transplantation: The effect of new HCV drugs on liver transplantation outcomes.1 passage
• Liver: PVT in cirrhosis, not always an innocent bystander.1 passage
• Liver: the gut is a key target of therapy in hepatic encephalopathy.1 passage
• Living donor liver transplantation: eliminating the wait for death in end-stage liver disease?1 passage
• Location is important: differentiation between ileal and colonic Crohn's disease.1 passage
• Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.1 passage
• Macrophages in intestinal inflammation and resolution: a potential therapeutic target in IBD.1 passage
• Major complications of bariatric surgery: endoscopy as first-line treatment.1 passage
• Maladaptive regeneration - the reawakening of developmental pathways in NASH and fibrosis.1 passage
• Management of NAFLD: a stage-based approach.1 passage
• Management of acute HCV infection in the era of direct-acting antiviral therapy.1 passage
• Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation.1 passage
• Management of diverticular disease.1 passage
• Management of functional constipation in children and adults.1 passage
• Management of refractory eosinophilic oesophagitis.1 passage
• Management of refractory typical GERD symptoms.1 passage
• Mechanisms and management of refractory coeliac disease.1 passage
• Mechanisms by which gut microorganisms influence food sensitivities.1 passage
• Mechanisms of hepatic stellate cell activation.1 passage
• Medical devices for the treatment of obesity.1 passage
• Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators.1 passage
• Metabolic rearrangements in primary liver cancers: cause and consequences.1 passage
• Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests.1 passage
• Microbiota in pancreatic health and disease: the next frontier in microbiome research.1 passage
• Mitochondrial function - gatekeeper of intestinal epithelial cell homeostasis.1 passage
• Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.1 passage
• Modelling hepatitis C therapy--predicting effects of treatment.1 passage
• Modern therapeutic approaches for the treatment of malignant liver tumours.1 passage
• Molecular and cellular mechanisms of liver fibrosis and its regression.1 passage
• Molecular subtypes in cancers of the gastrointestinal tract.1 passage
• Molecular subtypes of pancreatic cancer.1 passage
• Motility: Is 'ICC-opathy' present in gastroparesis-like syndrome?1 passage
• Mycobiota in gastrointestinal diseases.1 passage
• NAFLD and diabetes mellitus.1 passage
• NAFLD in children: new genes, new diagnostic modalities and new drugs.1 passage
• NAFLD. Accurate quantification of hepatic fat--is it important?1 passage
• Nanomedicines in gastroenterology and hepatology.1 passage
• Necrotizing enterocolitis: new insights into pathogenesis and mechanisms.1 passage
• Neonatal cholestasis: emerging molecular diagnostics and potential novel therapeutics.1 passage
• Neural plasticity in pancreatitis and pancreatic cancer.1 passage
• Neural reflex pathways in intestinal inflammation: hypotheses to viable therapy.1 passage
• Neuroimmunophysiology of the gut: advances and emerging concepts focusing on the epithelium.1 passage
• Neutrophils and neutrophil extracellular traps in the liver and gastrointestinal system.1 passage
• New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology.1 passage
• New insights into acute pancreatitis.1 passage
• New treatments and therapeutic targets for IBS and other functional bowel disorders.1 passage
• Next-generation robotics in gastrointestinal surgery.1 passage
• Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications.1 passage
• Non-conventional features of peripheral serotonin signalling - the gut and beyond.1 passage
• Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.1 passage
• Noninvasive biomarkers in NAFLD and NASH - current progress and future promise.1 passage
• Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD.1 passage
• Novel perspectives in the management of decompensated cirrhosis.1 passage
• Novel players in coeliac disease pathogenesis: role of the gut microbiota.1 passage
• Novel therapeutic targets in primary biliary cirrhosis.1 passage
• Obesity and gastrointestinal cancer: the interrelationship of adipose and tumour microenvironments.1 passage
• Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes.1 passage
• Oesophageal dysphagia: manifestations and diagnosis.1 passage
• Opioid misuse in gastroenterology and non-opioid management of abdominal pain.1 passage
• Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?1 passage
• Optimizing early upper gastrointestinal cancer detection at endoscopy.1 passage
• Optogenetic and chemogenetic techniques for neurogastroenterology.1 passage
• Organoid models of gastrointestinal cancers in basic and translational research.1 passage
• Oropharyngeal dysphagia: manifestations and diagnosis.1 passage
• Paediatric gastroenterology. On a knife-edge--weight-loss surgery for NAFLD in adolescents.1 passage
• Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors.1 passage
• Pancreatic cancer in 2015: Precision medicine in pancreatic cancer--fact or fiction?1 passage
• Pancreatic cancer stroma: an update on therapeutic targeting strategies.1 passage
• Pancreatic cancer: Classifying pancreatic cancer using gene expression profiling.1 passage
• Parkinson disease and the gut: new insights into pathogenesis and clinical relevance.1 passage
• Past, present and future perspectives in nonalcoholic fatty liver disease.1 passage
• Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases.1 passage
• Pathogenesis of biliary atresia: defining biology to understand clinical phenotypes.1 passage
• Patient optimization for surgery relating to Crohn's disease.1 passage
• Perianal fistulizing Crohn's disease: pathogenesis, diagnosis and therapy.1 passage
• Peroral endoscopic myotomy: an evolving treatment for achalasia.1 passage
• Placebo effects and their determinants in gastrointestinal disorders.1 passage
• Plasticity of the brush border - the yin and yang of intestinal homeostasis.1 passage
• Polyploidy in liver development, homeostasis and disease.1 passage
• Population screening and treatment of Helicobacter pylori infection.1 passage
• Position paper: The potential role of optical biopsy in the study and diagnosis of environmental enteric dysfunction.1 passage
• Post-infectious IBS, tropical sprue and small intestinal bacterial overgrowth: the missing link.1 passage
• Potential intestinal infection and faecal-oral transmission of SARS-CoV-2.1 passage
• Practical insights into gluten-free diets.1 passage
• Precision prevention of oesophageal adenocarcinoma.1 passage
• Primary biliary cholangitis: pathogenesis and therapeutic opportunities.1 passage
• Probiotics and prebiotics in intestinal health and disease: from biology to the clinic.1 passage
• Problems with extracellular recording of electrical activity in gastrointestinal muscle.1 passage
• Progress towards elimination goals for viral hepatitis.1 passage
• Proton-pump inhibitors: understanding the complications and risks.1 passage
• Recipient factors in faecal microbiota transplantation: one stool does not fit all.1 passage
• Redefining the IBDs using genome-scale molecular phenotyping.1 passage
• Regenerative medicine and cell-based approaches to restore pancreatic function.1 passage
• Regenerative medicine in 2015: Generating and regenerating the digestive system.1 passage
• Regulation and functional roles of chemokines in liver diseases.1 passage
• Regulation of intestinal lipid metabolism: current concepts and relevance to disease.1 passage
• Reimagining the diagnostic pathway for gastrointestinal cancer.1 passage
• Respiratory disease and the oesophagus: reflux, reflexes and microaspiration.1 passage
• Restoring, releasing or replacing adaptive immunity in chronic hepatitis B.1 passage
• Revisiting fibrosis in inflammatory bowel disease: the gut thickens.1 passage
• Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease.1 passage
• Role of endoscopy in early oesophageal cancer.1 passage
• Role of liver sinusoidal endothelial cells in liver diseases.1 passage
• Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer.1 passage
• Role of priority effects in the early-life assembly of the gut microbiota.1 passage
• SFED recommendations for IBD endoscopy during COVID-19 pandemic: Italian and French experience.1 passage
• Screening and diagnosis of HBV in low-income and middle-income countries.1 passage
• Secretory diarrhoea: mechanisms and emerging therapies.1 passage
• Serrated neoplasia-role in colorectal carcinogenesis and clinical implications.1 passage
• Sex matters: impact on pathogenesis, presentation and treatment of inflammatory bowel disease.1 passage
• Single-cell technologies in hepatology: new insights into liver biology and disease pathogenesis.1 passage
• Society for the Study of Celiac Disease position statement on gaps and opportunities in coeliac disease.1 passage
• Software for enhanced video capsule endoscopy: challenges for essential progress.1 passage
• Spatial heterogeneity in the mammalian liver.1 passage
• Stress-related mucosal disease in the critically ill patient.1 passage
• Systems biology in hepatology: approaches and applications.1 passage
• Tales from the crypt: new insights into intestinal stem cells.1 passage
• Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers.1 passage
• The Hippo pathway in intestinal regeneration and disease.1 passage
• The IBD interactome: an integrated view of aetiology, pathogenesis and therapy.1 passage
• The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on fermented foods.1 passage
• The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics.1 passage
• The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics.1 passage
• The bowel and beyond: the enteric nervous system in neurological disorders.1 passage
• The changing epidemiology of liver diseases in the Asia-Pacific region.1 passage
• The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments.1 passage
• The concept of gut rehabilitation and the future of visceral transplantation.1 passage
• The elusive case of human intraepithelial T cells in gut homeostasis and inflammation.1 passage
• The evolution and clinical impact of hepatitis B virus genome diversity.1 passage
• The evolving concept of acute kidney injury in patients with cirrhosis.1 passage
• The extracellular matrix of the gastrointestinal tract: a regenerative medicine platform.1 passage
• The four epidemiological stages in the global evolution of inflammatory bowel disease.1 passage
• The global burden of IBD: from 2015 to 2025.1 passage
• The gut microbiome and liver cancer: mechanisms and clinical translation.1 passage
• The gut microbiota and gastrointestinal surgery.1 passage
• The gut mycobiota: insights into analysis, environmental interactions and role in gastrointestinal diseases.1 passage
• The gut-liver axis and the intersection with the microbiome.1 passage
• The intestinal epithelial barrier: a therapeutic target?1 passage
• The metabolic role of vagal afferent innervation.1 passage
• The mucosal immune system: master regulator of bidirectional gut-brain communications.1 passage
• The multidisciplinary management of rectal cancer.1 passage
• The pancreatic cancer genome revisited.1 passage
• The promise of metabolic phenotyping in gastroenterology and hepatology.1 passage
• The promise of the gut microbiome as part of individualized treatment strategies.1 passage
• The role of diet in the aetiopathogenesis of inflammatory bowel disease.1 passage
• The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer.1 passage
• The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.1 passage
• The role of oral bacteria in inflammatory bowel disease.1 passage
• The role of short-chain fatty acids in microbiota-gut-brain communication.1 passage
• The role of telomeres and telomerase in cirrhosis and liver cancer.1 passage
• The role of the gut microbiota in NAFLD.1 passage
• The spectrum of noncoeliac gluten sensitivity.1 passage
• The unusual suspects--innate lymphoid cells as novel therapeutic targets in IBD.1 passage
• Therapeutic developments in pancreatic cancer: current and future perspectives.1 passage
• Therapeutic intervention in oropharyngeal dysphagia.1 passage
• Therapeutic options in oesophageal dysphagia.1 passage
• Therapeutic pipeline in nonalcoholic steatohepatitis.1 passage
• Therapy. Statins and liver disease: from concern to 'wonder' drugs?1 passage
• Timing of catheter drainage in infected necrotizing pancreatitis.1 passage
• Towards a more comprehensive concept for prebiotics.1 passage
• Towards a systems view of IBS.1 passage
• Transcriptional programmes underlying cellular identity and microbial responsiveness in the intestinal epithelium.1 passage
• Translating the gut microbiome: ready for the clinic?1 passage
• Transplantation: Allocation of liver transplants-a road to consensus.1 passage
• Treatment for unresectable or metastatic oesophageal cancer: current evidence and trends.1 passage
• Treatment of hepatitis C in difficult-to-treat patients.1 passage
• Triggering and resolution of inflammation in NASH.1 passage
• Tumour evolution in hepatocellular carcinoma.1 passage
• Understanding the mechanisms of faecal microbiota transplantation.1 passage
• Understanding the physiology of human defaecation and disorders of continence and evacuation.1 passage
• Understanding, predicting and achieving liver transplant tolerance: from bench to bedside.1 passage
• Urbanization and the gut microbiota in health and inflammatory bowel disease.1 passage
• Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure.1 passage
• Vagal neurocircuitry and its influence on gastric motility.1 passage
• Viral hepatitis and pregnancy.1 passage
• Viral hepatitis. HBV cure--can we pin our hopes on immunotherapy?1 passage
• Viral hepatitis: A new HCV cell culture model for the next clinical challenges.1 passage
• Viral hepatitis: cure of chronic hepatitis C--required length of follow-up?1 passage
• What's unique about acute pancreatitis in children: risk factors, diagnosis and management.1 passage
• Wnt-β-catenin signalling in liver development, health and disease.1 passage
• XIVth Little Brain Big Brain: next-generation enteric neuroscience.1 passage
• You are what you eat: diet, health and the gut microbiota.1 passage